Solid Biosciences' GAAP loss for 3 months of 2022 was $25.328 million, up 49.9% from $16.9 million in the previous year. Revenue decreased 42.3% to $1,925 million from $3,335 million a year earlier.
Solid Biosciences' GAAP loss for 3 months of 2022 was $25.328 million, up 49.9% from $16.9 million in the previous year. Revenue decreased 42.3% to $1,925 million from $3,335 million a year earlier. 
investors.solidbio.com
English (US) 